Wire · opportunities
Teva Wins FDA Approval for Monthly Schizophrenia Injection
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 October 2026 · Fusion42 review
Teva Pharmaceuticals received FDA approval for Weltruza, a once-monthly subcutaneous injectable olanzapine formulation to treat adults with schizophrenia, based on positive phase 3 trial results. The treatment improves adherence by avoiding daily oral medication and does not require loading doses or post-injection monitoring, though it carries known metabolic risks.
This Wire brief sits within Fusion42's coverage of Biotech, and 14 sources have reported it between 9 Oct 2026 and 10 Oct 2026.
◆ ◆ The Wire takeaway
You can now offer a once-monthly injectable for schizophrenia that reduces daily pill burden and monitoring needs. This approval opens paths to create or integrate treatments that tackle medication adherence in mental health.
◆ Coverage
14 sources · first reported 9 Oct 2026 · latest 10 Oct 2026
◆ Topics